JNJ - Johnson & Johnson

NYSE - Nasdaq Real Time Price. Currency in USD
145.56
+1.06 (+0.73%)
As of 10:41AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close144.50
Open144.71
Bid145.35 x 100
Ask145.40 x 100
Day's Range144.56 - 145.71
52 Week Range118.62 - 148.32
Volume1,525,786
Avg. Volume6,623,530
Market Cap390.389B
Beta (3Y Monthly)0.31
PE Ratio (TTM)255.82
EPS (TTM)0.57
Earnings DateJan 22, 2019
Forward Dividend & Yield3.60 (2.47%)
Ex-Dividend Date2018-11-26
1y Target Est147.06
Trade prices are not sourced from all markets
  • New jury fails to reach verdict in J&J South Carolina talc cancer trial
    Reuters3 hours ago

    New jury fails to reach verdict in J&J South Carolina talc cancer trial

    The case of Bertila Boyd-Bostic, who died of a rare form of cancer in 2017 at the age of 30, is the latest in a series of trials in the United States that centre around allegations that the company's talc-based powder contains cancer-causing asbestos. In May, a deadlocked jury at the Darlington County Court of Common Pleas in Charleston failed to reach a verdict in the first trial. J&J, which denies the allegations, to date has lost two trials and won three in the litigation over whether Johnson's Baby Powder causes mesothelioma, a tissue cancer closely linked to asbestos exposure.

  • PR Newswire4 hours ago

    ACUVUE OASYS with Transitions Light Intelligent Technology Named Among TIME's 'Best Inventions of 2018'

    First-of-its-kind contact lens corrects vision and adapts to changing light conditions JACKSONVILLE, Fla. , Nov. 16, 2018 /PRNewswire/ -- TIME has selected ACUVUE OASYS with Transitions Light Intelligent ...

  • New jury fails to reach verdict in J&J South Carolina talc cancer trial
    Reuters14 hours ago

    New jury fails to reach verdict in J&J South Carolina talc cancer trial

    The case of Bertila Boyd-Bostic, who died of a rare form of cancer in 2017 at the age of 30, is the latest in a series of trials in the United States that center around allegations that the company's talc-based powder contains cancer-causing asbestos. In May, a deadlocked jury at the Darlington County Court of Common Pleas in Charleston failed to reach a verdict in the first trial. J&J, which denies the allegations, to date has lost two trials and won three in the litigation over whether Johnson's Baby Powder causes mesothelioma, a tissue cancer closely linked to asbestos exposure.

  • Johnson & Johnson (JNJ) Up 3.4% Since Last Earnings Report: Can It Continue?
    Zacksyesterday

    Johnson & Johnson (JNJ) Up 3.4% Since Last Earnings Report: Can It Continue?

    Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Why Johnson & Johnson's Up 3% So Far in 2018
    Motley Foolyesterday

    Why Johnson & Johnson's Up 3% So Far in 2018

    Here's what's keeping the healthcare giant in check.

  • Should You Be Pleased About The CEO Pay At Johnson & Johnson’s (NYSE:JNJ)
    Simply Wall St.yesterday

    Should You Be Pleased About The CEO Pay At Johnson & Johnson’s (NYSE:JNJ)

    Alex Gorsky became the CEO of Johnson & Johnson (NYSE:JNJ) in 2012. First, this article will compare CEO compensation with compensation at other large companies. Next, we’ll consider growth that Read More...

  • Why Wall Street Is Still Bullish on Tandem Stock
    Market Realistyesterday

    Why Wall Street Is Still Bullish on Tandem Stock

    This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating. The mean rating for Tandem Diabetes Care stock is 2.1 with a price target of $52.8, implying an upside potential of 65% over the closing price of $32.0 on November 13.

  • Jury clears J&J of liability in California talc cancer case
    Reuters2 days ago

    Jury clears J&J of liability in California talc cancer case

    The jury in Humboldt County Superior Court in Eureka, California rejected claims by Carla Allen who said that her mesothelioma, a tissue cancer closely linked to asbestos exposure, was caused by the company's talc products, including Johnson's Baby Powder. J&J denies the allegations, saying decades of scientific testing and regulatory approvals have shown its talc to be safe and asbestos-free.

  • Reuters2 days ago

    Jury clears J&J of liability in California talc cancer case

    The jury in Humboldt County Superior Court in Eureka, California rejected claims by Carla Allen who said that her mesothelioma, a tissue cancer closely linked to asbestos exposure, was caused by the company's talc products, including Johnson's Baby Powder. J&J denies the allegations, saying decades of scientific testing and regulatory approvals have shown its talc to be safe and asbestos-free.

  • AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study
    Zacks2 days ago

    AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study

    AbbVie's (ABBV) Mavyret demonstrates high virologic cure rates in a study evaluating it for an expanded patient population.

  • Tandem Diabetes Care’s Operational Performance
    Market Realist2 days ago

    Tandem Diabetes Care’s Operational Performance

    For fiscal 2018 and 2019, Tandem Diabetes Care’s gross margins are expected at 47.13% and 51.78%, respectively, compared with 40% in fiscal 2017. The fiscal 2018 gross margins of peers DexCom (DXCM), Insulet (PODD), and Johnson & Johnson (JNJ) are expected at 64.29%, 65.59%, and 70.43%, respectively. Tandem Diabetes Care incurred selling, general, and administrative expenses of $29.51 million in the third quarter of 2018, versus $20.12 million in the third quarter of 2017.

  • Why Tandem Should Be on Your Stock Radar
    Market Realist2 days ago

    Why Tandem Should Be on Your Stock Radar

    Tandem Diabetes Care’s (TNDM) key focus is its t:slim X2 insulin delivery system, which is designed to display continuous glucose monitoring directly on pumps’ home screens. This is the only pump capable of remote feature updates on the US market. Tandem also sells disposable products such as cartridges and infusion sets that are used with its pumps and replaced periodically. In August 2018, Tandem began the commercialization of the t:slim X2 in key regions outside the United States.

  • Here’s how to easily reduce your investment risk just at the right time
    MarketWatch2 days ago

    Here’s how to easily reduce your investment risk just at the right time

    Mike Loewengart of E-Trade discusses equal-weighted and bond ETFs, and actively managed funds for diversification.

  • Gauging Analysts’ Views on TransEnterix Stock
    Market Realist2 days ago

    Gauging Analysts’ Views on TransEnterix Stock

    In November, of the five analysts covering TransEnterix (TRXC), three have given it “buy” or higher ratings, and two have given it “hold” ratings. 

  • Financial Times3 days ago

    [$$] The Theranos tale exposes the dangers lurking in Silicon Valley

    At some point, probably next year, Elizabeth Holmes, the charismatic founder of Theranos, and her ex-boyfriend Ramesh “Sunny” Balwani, the group’s former chief operating officer, will stand trial, charged with defrauding investors, doctors and patients. Somewhere among the court reporters will be investigative journalist John Carreyrou, completing an assignment that started in February 2015 when he received a tip about Ms Holmes, a Silicon Valley prodigy promising to shake up healthcare with a revolutionary blood-testing system. , his first book, which chronicles the rise and fall of Theranos.

  • 3 Top Healthcare Stocks to Buy in November
    Motley Fool3 days ago

    3 Top Healthcare Stocks to Buy in November

    An insurer, a medical device company, and a healthcare Goliath could all be smart additions to portfolios this month.

  • Understanding TransEnterix’s Operational Performance
    Market Realist3 days ago

    Understanding TransEnterix’s Operational Performance

    For 2018 and 2019, TransEnterix’s gross margins are expected to be 41.40% and 48.76%, respectively, compared to its gross margin of 5.4% in 2017. In comparison, the 2018 gross margins of its peers Intuitive Surgical (ISRG), Johnson & Johnson (JNJ), and Stryker (SYK) are expected to be 71.01%, 70.43%, and 66.29%, respectively. TransEnterix incurred general and administrative expenses of $3.69 million in the third quarter compared to $2.92 million in the third quarter of 2017 primarily due to higher personnel costs and outsourced services expenses.

  • How TransEnterix Has Been Performing in November
    Market Realist3 days ago

    How TransEnterix Has Been Performing in November

    TransEnterix (TRXC) is a medical device company focused on digitizing the interface between surgeons and patients for the improvement of minimally invasive surgery. TransEnterix’s Senhance surgical system digitizes laparoscopic minimally invasive surgery and allows for robotic precision, haptic feedback, surgeon camera control, and improved ergonomics. TransEnterix generated total revenue of $5.42 million in the third quarter compared to $183,000 in the comparable period of 2017.

  • Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
    Zacks4 days ago

    Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know

    Johnson & Johnson (JNJ) closed at $145.62 in the latest trading session, marking a +0.19% move from the prior day.

  • Stock Market Power Rankings: Last Call for Facebook
    Motley Fool4 days ago

    Stock Market Power Rankings: Last Call for Facebook

    They're big, beautiful, and ranked from 1 to 50.

  • Johnson & Johnson to Participate in the Citi's 2018 Global Healthcare Conference
    PR Newswire4 days ago

    Johnson & Johnson to Participate in the Citi's 2018 Global Healthcare Conference

    NEW BRUNSWICK, N.J. , Nov. 12, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Citi's 2018 Global Healthcare Conference on Wednesday, December 5 th , at the Lotte New York Palace ...

  • PR Newswire4 days ago

    Singapore National Eye Centre, Singapore Eye Research Institute And Johnson & Johnson Vision Set Sights On Halting Global Myopia Epidemic

    New US$26.35 Million Collaboration Seeks Prevention and Treatment Solutions to Address Rising Burden of Condition SINGAPORE , Nov. 12, 2018 /PRNewswire/ -- The Singapore National Eye Centre (SNEC), the ...

  • PR Newswire4 days ago

    Singapore National Eye Centre, Singapore Eye Research Institute And Johnson & Johnson Vision Set Sights On Halting Global Myopia Epidemic

    The first-of-its-kind public-private strategic partnership in Asia focused on myopia will create a deeper understanding of how the condition develops, how it progresses and how it may be intercepted. It will focus on developing predictive tools to identify those who may be at risk to develop high myopia, conduct research on the underlying mechanisms of myopia, progress novel therapies, and discover and validate methods to prevent the onset and progression of the condition.

  • Hedge Fund Sentiment is Turning Against Johnson & Johnson (JNJ)
    Insider Monkey5 days ago

    Hedge Fund Sentiment is Turning Against Johnson & Johnson (JNJ)

    Insider Monkey finished processing more than 700 13F filings made by hedge funds and prominent investors. These filings show these funds’ portfolio positions as of June 30. What do these smart investors think about Johnson & Johnson (NYSE:JNJ)? Overall, they’re fairly bullish on the stock, as 10.2% of the hedge funds tracked by Insider Monkey’s […]